David Melamed, PhD,  —

The U.S. Patent and Trademark Office has issued a new patent to Catalyst Pharmaceuticals covering the company’s rights to Firdapse (amifampridine), a treatment for Lambert-Eaton myasthenic syndrome (LEMS). The patent (No. 10,793,893), “Methods of administering 3,4-diaminopyridine,” expires on April 7, 2034. Catalyst’s rights over Firdapse…

A $1.95 million federal grant has been awarded to researchers investigating the underlying cause of autoimmune diseases, which include Lambert-Eaton myasthenic syndrome (LEMS). Autoimmune disorders, collectively characterized by immune system attack against the body’s own tissues, are the third most common disease type in humans (after cancer and…